We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

47 hedge funds and large institutions have $17M invested in Titan Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

866% more call options, than puts

Call options by funds: $1.18M | Put options by funds: $122K

267% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 3

160% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 5

21% more funds holding

Funds holding: 39 → 47 (+8)

19% more capital invested

Capital invested by funds: $14.3M → $17M (+$2.74M)

Holders
47
Holders Change
+8
Holders Change %
+20.51%
% of All Funds
1.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
11
Reduced
3
Closed
5
Calls
$1.18M
Puts
$122K
Net Calls
+$1.06M
Net Calls Change
-$545K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$311K
2
AQR Capital Management
AQR Capital Management
Connecticut
+$272K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$272K
4
AIM
Acrospire Investment Management
Illinois
+$175K
5
PMG
ProVise Management Group
Florida
+$155K

Top Sellers

Rank Fund Capital Flow
1
GS
Gagnon Securities
New York
-$340K
2
Citadel Advisors
Citadel Advisors
Florida
-$85K
3
VKH
Virtu KCG Holdings
New York
-$38.8K
4
Creative Planning
Creative Planning
Kansas
-$27K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$19.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
RHBC
26
R.H. Bluestein & Co
Michigan
$118K – – –
New York State Common Retirement Fund
27
New York State Common Retirement Fund
New York
$114K – – –
Citigroup
28
Citigroup
New York
$98K +$77.7K +4 +400%
SG Americas Securities
29
SG Americas Securities
New York
$96K +$97.1K +5 New
TDC
30
Thompson Davis & Co
Virginia
$95K – – –
Walleye Trading
31
Walleye Trading
New York
$89K +$77.7K +4 New
RhumbLine Advisers
32
RhumbLine Advisers
Massachusetts
$80K – – –
Morgan Stanley
33
Morgan Stanley
New York
$75K +$38.8K +2 +100%
NFA
34
Nationwide Fund Advisors
Ohio
$71K – – –
CS
35
Credit Suisse
Switzerland
$70K -$19.4K -1 -25%
BA
36
BlackRock Advisors
Delaware
$66K +$19.4K +1 +50%
AIG
37
American International Group
New York
$63.8K – – –
PPA
38
Parametric Portfolio Associates
Washington
$62K +$58.3K +3 New
Wells Fargo
39
Wells Fargo
California
$59K +$38.8K +2 +200%
DADC
40
D.A. Davidson & Co
Montana
$58K – – –
Deutsche Bank
41
Deutsche Bank
Germany
$18K – – –
BCM
42
Blume Capital Management
California
$15K – – –
AIS
43
Accurate Investment Solutions
Pennsylvania
$12K +$19.4K +1 New
AIM
44
Arcadia Investment Management
Michigan
$11K – – –
UBS Group
45
UBS Group
Switzerland
$11K +$19.4K +1 New
PMG
46
ProVise Management Group
Florida
$8K +$155K +8 New
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$7.52K – – –
IWMPD
48
Integrated Wealth Management (Palm Desert)
California
$5K – – –
KF
49
Krilogy Financial
Missouri
$5K – – –
MFS
50
MSI Financial Services
Massachusetts
$5K – – –
1
2
3

TTNP Hedge Fund Activity: Q3 2016 in Review

47 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q3 2016, worth a combined $17M — up 19% from $14.3M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new TTNP positions and 5 closed out — a net gain of 8 holders — while 11 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Group, adding an estimated $311K. The largest seller was Gagnon Securities, exiting entirely with an estimated $340K sold.

  • 47 institutional investors held Titan Pharmaceuticals (TTNP) as of Q3 2016, up from 39 in Q2 2016.
  • Funds reported $17M of Titan Pharmaceuticals stock for Q3 2016, up 19% quarter-over-quarter.
  • 13 funds opened new Titan Pharmaceuticals positions in Q3 2016 and 5 closed out, a net change of +8 holders.
  • The largest Titan Pharmaceuticals buyer in Q3 2016 was Vanguard Group, an estimated $311K added.
  • The largest Titan Pharmaceuticals seller in Q3 2016 was Gagnon Securities, an estimated $340K sold.

Based on aggregated 13F filings for Q3 2016.